Treatment library
Loading treatment roster
Preparing current medications, procedures, devices, and historical context.
Treatment library
Preparing current medications, procedures, devices, and historical context.
A short-term sympathomimetic appetite suppressant that predates the modern GLP-1 era by decades. It remains relevant mainly as a lower-cost, older-style obesity medication.
FDA-approved for short-term obesity treatment as an adjunct to calorie restriction.
Sympathomimetic appetite suppression
Coverage varies, but generic cash-pay pricing is generally more accessible than newer brands.
Sympathomimetic appetite suppression
A short-term sympathomimetic appetite suppressant that predates the modern GLP-1 era by decades. It remains relevant mainly as a lower-cost, older-style obesity medication.
medication
current
1959
generic diethylpropion
diethylpropion
Multiple generic manufacturers
Yes.
diethylpropion
Usually a lower-cost generic option compared with branded obesity therapies.
Coverage varies, but generic cash-pay pricing is generally more accessible than newer brands.
Relevant mostly in older short-term stimulant prescribing patterns.
Diethylpropion remains part of the older pharmacotherapy lineage rather than the current center of gravity in obesity care.
Stimulant-related cardiovascular, sleep, and dependence concerns limit use and appeal.
insomnia, dry mouth, elevated heart rate, restlessness, constipation
Sympathomimetic appetite suppression
Immediate-release and controlled-release oral formulations are used for short-term treatment.
Oral tablet.
These are the official or reference sources used to anchor this treatment profile.
Treatment availability, dosing, cash pricing, and insurance coverage change often. Verify current details with your clinician, pharmacist, surgeon, device program, and insurer before starting, switching, or paying for treatment.